+ A
A -
NEW DELHI: Russia’s sovereign wealth fund and an Indian pharmaceutical company said on Wednesday they had agreed to distribute 100 million doses of a potential coronavirus vaccine in India.
Deliveries of the Sputnik V vaccine could take place as early as the end of the year, subject to approval by Indian regulatory authorities and the successful completion of trials, a joint release said.
The Russian Direct Investment Fund (RDIF) and Dr Reddy’s Laboratories Limited have also agreed to cooperate on clinical trials in India, the release said.
The Sputnik V vaccine is based on a human adenoviral vector platform and is undergoing clinical trials for the coronavirus pandemic.
The first two phases of the trials of the vaccine have shown promising results, GV Prasad, managing director of Dr Reddy’s Laboratories was quoted as saying.
The third phase of trials would be conducted by Dr Reddy’s in India to ensure safety and efficacy for the Indian population and to meet requirements of Indian regulators, Prasad said. (DPA)
Deliveries of the Sputnik V vaccine could take place as early as the end of the year, subject to approval by Indian regulatory authorities and the successful completion of trials, a joint release said.
The Russian Direct Investment Fund (RDIF) and Dr Reddy’s Laboratories Limited have also agreed to cooperate on clinical trials in India, the release said.
The Sputnik V vaccine is based on a human adenoviral vector platform and is undergoing clinical trials for the coronavirus pandemic.
The first two phases of the trials of the vaccine have shown promising results, GV Prasad, managing director of Dr Reddy’s Laboratories was quoted as saying.
The third phase of trials would be conducted by Dr Reddy’s in India to ensure safety and efficacy for the Indian population and to meet requirements of Indian regulators, Prasad said. (DPA)
